603127 昭衍新药
已收盘 04-10 15:00:00
资讯
新帖
简况
港股异动 | 昭衍新药(06127)盘中涨超4% 安评行业或迎来量价齐升 公司新签订单金额环比持续增长
智通财经 · 04-10 10:57
港股异动 | 昭衍新药(06127)盘中涨超4% 安评行业或迎来量价齐升 公司新签订单金额环比持续增长
昭衍新药（603127）披露股票交易异常波动公告，4月3日股价上涨0.41%
证券之星 · 04-03
昭衍新药（603127）披露股票交易异常波动公告，4月3日股价上涨0.41%
去年下半年增持昭衍新药、建仓特宝生物 中欧基金葛兰自购旗下独管医药基金
澎湃新闻 · 04-01
去年下半年增持昭衍新药、建仓特宝生物 中欧基金葛兰自购旗下独管医药基金
昭衍新药：股票交易异常波动
南方财经网 · 03-31
昭衍新药：股票交易异常波动
港股异动 | 昭衍新药(06127)早盘涨超14% 全年纯利同比增超3倍 实验猴涨价贡献近5亿元利润
智通财经 · 03-31
港股异动 | 昭衍新药(06127)早盘涨超14% 全年纯利同比增超3倍 实验猴涨价贡献近5亿元利润
昭衍新药最新公告：2025年度净利润2.98亿元同比增长302%
证券之星 · 03-30
昭衍新药最新公告：2025年度净利润2.98亿元同比增长302%
3月30日昭衍新药涨6.15%，中欧医疗创新股票A基金重仓该股
证券之星 · 03-30
3月30日昭衍新药涨6.15%，中欧医疗创新股票A基金重仓该股
每周股票复盘：昭衍新药（603127）参投基金出资调整
证券之星 · 03-29
每周股票复盘：昭衍新药（603127）参投基金出资调整
股市必读：昭衍新药（603127）今年截至3月26日累计跌幅已超20%
证券之星 · 03-27
股市必读：昭衍新药（603127）今年截至3月26日累计跌幅已超20%
昭衍新药：公司将于3月31日披露财报
每日经济新闻 · 03-26
昭衍新药：公司将于3月31日披露财报
每周股票复盘：昭衍新药（603127）股东拟减持不超3%股份
证券之星 · 03-22
每周股票复盘：昭衍新药（603127）股东拟减持不超3%股份
昭衍新药（603127）披露董事会会议安排公告，3月18日股价下跌0.14%
证券之星 · 03-18
昭衍新药（603127）披露董事会会议安排公告，3月18日股价下跌0.14%
股东清仓减持引发跌停 昭衍新药紧急调整方案
经济参考网 · 03-18
股东清仓减持引发跌停 昭衍新药紧急调整方案
股东拟“清仓式”减持，603127股价跌停！公司最新回应：减持力度超出市场预期
每日经济新闻 · 03-17
股东拟“清仓式”减持，603127股价跌停！公司最新回应：减持力度超出市场预期
3月17日昭衍新药（603127）龙虎榜数据：机构净卖出2.02亿元，北向资金净卖出269.05万元
证券之星 · 03-17
3月17日昭衍新药（603127）龙虎榜数据：机构净卖出2.02亿元，北向资金净卖出269.05万元
昭衍新药遭股东“清仓式”减持 业绩预增超两倍为何还留不住人？
21世纪经济报道 · 03-17
昭衍新药遭股东“清仓式”减持 业绩预增超两倍为何还留不住人？
异动快报：昭衍新药（603127）3月17日13点21分触及跌停板
证券之星 · 03-17
异动快报：昭衍新药（603127）3月17日13点21分触及跌停板
昭衍新药股东顾晓磊及其一致行动人顾美芳拟清仓式减持公司A股股份
北京商报 · 03-16
昭衍新药股东顾晓磊及其一致行动人顾美芳拟清仓式减持公司A股股份
昭衍新药股东拟减持不超过4.1%股份，减持期为3月20日至6月19日
美股速递 · 03-16
昭衍新药股东拟减持不超过4.1%股份，减持期为3月20日至6月19日
昭衍新药(06127)进一步认购金融产品
智通财经 · 03-16
昭衍新药(06127)进一步认购金融产品
加载更多
公司概况
公司名称：
北京昭衍新药研究中心股份有限公司
所属行业：
研究和试验发展
上市日期：
2017-08-25
主营业务：
北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是。公司同时具备中国NMPA、美国FDA、经合组织OECD、韩国MFDS、日本PMDA等GLP资质；2025年9月公司北京及太仓设施通过了OECD的GLP现场检查及复查。
发行价格：
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":38.28,"timestamp":1775804400000,"preClose":37,"halted":0,"volume":44050485,"delay":0,"changeRate":0.0346,"floatShares":630000000,"shares":749000000,"eps":0.6961,"marketStatus":"已收盘","change":1.28,"latestTime":"04-10 15:00:00","open":37.01,"high":38.73,"low":36.8,"amount":1668000000,"amplitude":0.0522,"askPrice":38.28,"askSize":157,"bidPrice":38.27,"bidSize":1638,"shortable":0,"etf":0,"ttmEps":0.6961,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":37,"symbolType":"stock","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":40.7,"lowLimit":33.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749348220,"isCdr":false,"pbRate":3.45,"roa":"--","peRate":54.992099,"roe":"3.63%","epsLYR":0.4,"committee":0.687595,"marketValue":28685000000,"turnoverRate":0.0699,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-13。","hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":22.48,"timestamp":1775808560006,"preClose":21.68,"halted":0,"volume":7052688,"delay":0,"premium":"-48.76"},"floatMarketCap":24130000000},"requestUrl":"/m/hq/s/603127","defaultTab":"news","newsList":[{"id":"2626168384","title":"港股异动 | 昭衍新药(06127)盘中涨超4% 安评行业或迎来量价齐升 公司新签订单金额环比持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2626168384","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626168384?lang=zh_cn&edition=full","pubTime":"2026-04-10 10:57","pubTimestamp":1775789879,"startTime":"0","endTime":"0","summary":"长江证券发布研报称，当前安评行业或迎来量价齐升。2025年业绩方面，昭衍新药收入16.58亿元，同比下滑17.87%；归母净利润2.98亿元，同比增长302.08%；扣非净利润3.11亿元，同比增长1221.30%。业务亮点方面，2025Q4新签订单金额爆发式增长。2025Q4单季度新签订单金额达9.60亿元，同比增长118.2%，已非常接近历史单季度最高水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1141","BK4585","BK4588","06127","BK0216","603127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624659313","title":"昭衍新药（603127）披露股票交易异常波动公告，4月3日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624659313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624659313?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:24","pubTimestamp":1775208259,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，昭衍新药报收于36.6元，较前一交易日上涨0.41%，最新总市值为274.26亿元。该股当日开盘36.16元，最高37.25元，最低35.03元，成交额达15.89亿元，换手率为6.92%。公司于2026年4月1日披露《股票交易异常波动公告》。公告显示，昭衍新药股票于2026年3月27日、3月30日和3月31日连续3个交易日内收盘价格涨幅偏离值累计超过20%，构成股票交易异常波动。董事会确认无应披露未披露事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK1141","BK0216","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624543215","title":"去年下半年增持昭衍新药、建仓特宝生物 中欧基金葛兰自购旗下独管医药基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2624543215","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624543215?lang=zh_cn&edition=full","pubTime":"2026-04-01 07:27","pubTimestamp":1774999620,"startTime":"0","endTime":"0","summary":"2025年下半年，葛兰旗下3只基金的内部持有情况出现明显分化。3月31日，中欧基金投资总监、明星基金经理葛兰在管的3只公募基金披露2025年报，其隐形重仓股也随之曝光。具体来看，同为医药主题的中欧医疗健康、中欧医疗创新均大幅增持了昭衍新药，同时中欧医疗创新还重新买回了奥浦迈、博腾股份、三生国健，并首次建仓特宝生物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013690999074.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013690999074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["160635","BK1141","688278","BK0239","06127","BK0216","603127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623079833","title":"昭衍新药：股票交易异常波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2623079833","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623079833?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:35","pubTimestamp":1774949701,"startTime":"0","endTime":"0","summary":"南财智讯3月31日电，昭衍新药公告，公司股票于2026年3月27日、3月30日和3月31日连续3个交易日内收盘价格涨幅偏离值累计超过20%，构成股票交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690516776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603127","BK0216","06127","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623366376","title":"港股异动 | 昭衍新药(06127)早盘涨超14% 全年纯利同比增超3倍 实验猴涨价贡献近5亿元利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2623366376","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623366376?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:37","pubTimestamp":1774921027,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药(06127)早盘涨超14%，截至发稿，涨14.54%，报22.3港元，成交额7651.06万港元。消息面上，昭衍新药发布年度业绩，2025年，公司实现营业收入16.58亿元，同比下降17.87%；归属于上市公司股东的净利润2.98亿元，同比增长302.08%。另外，公司整体在手订单金额约为26亿元，新签订单金额约为26亿元，同比均有所增长。公告显示，净利润的增长主要源于生物资产公允价值变动带来的收益。期内，生物资产公允价值变动带来净收益4.76亿元。据悉，昭衍新药的生物资产主要是用于非临床项目评价的非人灵长类实验模型，也就是所谓的“实验猴”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ee4d118e55b1b421073820cd0cff0613","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","603127","BK0216","BK1576","BK1141","BK4585","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623191103","title":"昭衍新药最新公告：2025年度净利润2.98亿元同比增长302%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623191103","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623191103?lang=zh_cn&edition=full","pubTime":"2026-03-30 18:39","pubTimestamp":1774867187,"startTime":"0","endTime":"0","summary":"昭衍新药(603127.SH)公告称，公司发布2025年年度报告，实现营业收入16.58亿元，同比下降17.87%；归属于上市公司股东的净利润为2.98亿元，同比增长302.08%。公司拟向全体股东每10股派发现金红利1.2元(含税)。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000028589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623139778","title":"3月30日昭衍新药涨6.15%，中欧医疗创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623139778","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623139778?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:24","pubTimestamp":1774859040,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日昭衍新药涨6.15%，收盘报32.1元，换手率7.35%，成交量46.32万手，成交额14.67亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共45家，其中持有数量最多的公募基金为中欧基金的中欧医疗创新股票A。中欧医疗创新股票A目前规模为41.8亿元，最新净值1.4332，较上一交易日上涨5.51%，近一年上涨14.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","159891","06127","BK1576","BK1141","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387155","title":"每周股票复盘：昭衍新药（603127）参投基金出资调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623387155?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:13","pubTimestamp":1774717989,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，昭衍新药报收于30.24元，较上周的28.1元上涨7.62%。本周，昭衍新药3月27日盘中最高价报30.24元。普通合伙人北京崇德英盛投资管理有限公司将其持有的2000万元未实缴出资份额转让，其中500万元转让给中富创业投资（北京）有限公司，500万元转让给左从林，1000万元转让给刘增玉。本次变更后，普通合伙人认缴比例由23.33%降至1.11%。该基金已在中国证券投资基金业协会完成备案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","06127","603127","BK1576","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622086039","title":"股市必读：昭衍新药（603127）今年截至3月26日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622086039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622086039?lang=zh_cn&edition=full","pubTime":"2026-03-27 01:07","pubTimestamp":1774544829,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，昭衍新药报收于27.49元，下跌2.14%，换手率1.86%，成交量11.73万手，成交额3.26亿元。来自资金流向：3月26日主力资金净流出2326.06万元，占总成交额7.14%，散户资金净流入3599.41万元。交易信息汇总股价提醒3月26日昭衍新药收盘报27.49元，跌2.14%，当日成交1172.57万元。根据收盘数据统计，该股当年累计跌幅20.93%。该股最近90天内共有3家机构给出评级，买入评级2家；过去90天内机构目标均价为39.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700002606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","603127","BK1576","06127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622832558","title":"昭衍新药：公司将于3月31日披露财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2622832558","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622832558?lang=zh_cn&edition=full","pubTime":"2026-03-26 15:48","pubTimestamp":1774511307,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问贵司何时出财报？昭衍新药（603127.SH）3月26日在投资者互动平台表示，公司将于3月31日披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685499439.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685499439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621479693","title":"每周股票复盘：昭衍新药（603127）股东拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2621479693","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621479693?lang=zh_cn&edition=full","pubTime":"2026-03-22 01:54","pubTimestamp":1774115653,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，昭衍新药报收于28.1元，较上周的32.41元下跌13.3%。本周，昭衍新药3月16日盘中最高价报32.86元。公司公告汇总北京昭衍新药研究中心股份有限公司股东顾晓磊及其一致行动人顾美芳合计减持比例由不超过公司总股本的4.1026%调整为不超过3.00%。其中，顾晓磊拟减持不超过15,061,800股，占比不超过2.01%；顾美芳拟减持不超过7,418,400股，占比不超过0.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK1141","BK0216","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620997254","title":"昭衍新药（603127）披露董事会会议安排公告，3月18日股价下跌0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620997254","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620997254?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:03","pubTimestamp":1773842596,"startTime":"0","endTime":"0","summary":"截至2026年3月18日收盘，昭衍新药报收于29.28元，较前一交易日下跌0.14%，最新总市值为219.41亿元。该股当日开盘28.72元，最高29.89元，最低28.6元，成交额达8.19亿元，换手率为4.48%。近日，昭衍新药发布H股公告，披露公司董事会将于2026年3月30日举行会议，以考虑及通过本集团截至2025年12月31日止的年度业绩，考虑建议派发末期股息（如有），以及处理其他事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800040411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127","BK1576","BK1141","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620259742","title":"股东清仓减持引发跌停 昭衍新药紧急调整方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2620259742","media":"经济参考网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620259742?lang=zh_cn&edition=full","pubTime":"2026-03-18 21:20","pubTimestamp":1773840000,"startTime":"0","endTime":"0","summary":"3月16日晚间，CRO（医药研发外包服务）头部企业昭衍新药（603127.SH）披露股东“清仓式”减持计划，引发市场剧烈震荡。3月17日公司A股股价跌停、H股下跌超11%，公司随后迅速发布更正公告，下调减持比例并优化减持方式。对此，《经济参考报》记者致电昭衍新药，尝试了解公司发布更正公告下调股东减持比例是否受到股价下跌的影响，昭衍新药方面表示：“确实有这方面的考虑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183676233241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","603127","BK1141","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424582","title":"股东拟“清仓式”减持，603127股价跌停！公司最新回应：减持力度超出市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424582","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620424582?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:53","pubTimestamp":1773748380,"startTime":"0","endTime":"0","summary":"3月17日，CRO龙头昭衍新药A股跌停，H股重挫超10%。 引发此次股价地震的，是一则“清仓式”减持公告。 公司3月16日晚间对外披露关于股东减持A股股份计划公告。上述股东此前已在陆续减持，但此次减持力度超出市场预期，因此市场反应较大。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-03-17/doc-inhrieim8011455.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-17/doc-inhrieim8011455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620344094","title":"3月17日昭衍新药（603127）龙虎榜数据：机构净卖出2.02亿元，北向资金净卖出269.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620344094","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620344094?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:17","pubTimestamp":1773739021,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年3月17日公布的交易公开信息显示，昭衍新药因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年3月17日收盘，昭衍新药报收于29.32元，下跌10.01%，换手率4.57%，成交量28.83万手，成交额8.55亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出2.02亿元，北向资金合计净卖出269.05万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700029659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","603127","BK1141","BK1576","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620024446","title":"昭衍新药遭股东“清仓式”减持 业绩预增超两倍为何还留不住人？","url":"https://stock-news.laohu8.com/highlight/detail?id=2620024446","media":"21世纪经济报道","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620024446?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:01","pubTimestamp":1773730898,"startTime":"0","endTime":"0","summary":"3月17日，对于CRO（医药研发外包服务）龙头昭衍新药（603127.SH，06127.HK）的投资者而言，是一个颇不平静的交易日。继前一日发布股东减持计划公告后，昭衍新药今日开盘即跳空低开，盘中一度重挫逾9%，截至发稿时股价仍徘徊在底部区域，市场恐慌情绪可见一斑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603173674511327.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603173674511327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","06127","BK0216","603127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620649448","title":"异动快报：昭衍新药（603127）3月17日13点21分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2620649448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620649448?lang=zh_cn&edition=full","pubTime":"2026-03-17 13:25","pubTimestamp":1773725124,"startTime":"0","endTime":"0","summary":"证券之星3月17日盘中消息，13点21分昭衍新药触及跌停板。其所属行业医疗服务目前下跌。领涨股为*ST生物。该股为健康中国，创新药，医药概念热股，当日健康中国概念上涨0.69%，创新药概念上涨0.41%，医药概念上涨0.16%。3月16日的资金流向数据方面，主力资金净流出1388.82万元，占总成交额4.77%，游资资金净流出1183.65万元，占总成交额4.07%，散户资金净流入2572.47万元，占总成交额8.84%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700019711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127","BK1576","BK1141","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619469088","title":"昭衍新药股东顾晓磊及其一致行动人顾美芳拟清仓式减持公司A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619469088","media":"北京商报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619469088?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:05","pubTimestamp":1773669930,"startTime":"0","endTime":"0","summary":"北京商报讯3月16日晚间，昭衍新药（603127）发布公告显示，公司股东顾晓磊及其一致行动人顾美芳拟清仓式减持公司A股股份。具体来看，顾晓磊及其一致行动人顾美芳目前分别持有公司A股股份2042.05万股、1032.2万股，持股比例分别约为2.73%、1.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603163673427859.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163673427859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","BK1141","603127","399300","BK1576","159982","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192887526","title":"昭衍新药股东拟减持不超过4.1%股份，减持期为3月20日至6月19日","url":"https://stock-news.laohu8.com/highlight/detail?id=1192887526","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192887526?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:47","pubTimestamp":1773658035,"startTime":"0","endTime":"0","summary":"昭衍新药（603127.SS）近日发布公告称，公司部分股东计划通过集中竞价或大宗交易方式，在2024年3月20日至6月19日期间，合计减持不超过公司总股本4.1%的股份。\n此次减持计划涉及多位股东，其减持行为将根据市场情况、公司股价等因素择机进行。减持股份来源均为公司首次公开发行前已持有的股份。\n股东减持可能会对二级市场股价造成一定压力，投资者需关注相关风险。公司表示，本次减持计划不会导致公司控制权发生变更，也不会对公司的持续性经营产生重大影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619060455","title":"昭衍新药(06127)进一步认购金融产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2619060455","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619060455?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:13","pubTimestamp":1773652406,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)发布公告，于2026年3月16日(交易时间后)，本集团成员公司透过中信证券及其附属公司认购该等中信证券金融产品且于本公告日期仍未到期的该等中信证券金融产品合计投资总额为人民币4.6亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","06127","BK0216","159940","603127"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776002798109,"stockEarnings":[{"period":"1week","weight":0.0459},{"period":"1month","weight":0.1292},{"period":"3month","weight":-0.091},{"period":"6month","weight":0.1359},{"period":"1year","weight":1.1537},{"period":"ytd","weight":0.0934}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74934万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是。公司同时具备中国NMPA、美国FDA、经合组织OECD、韩国MFDS、日本PMDA等GLP资质；2025年9月公司北京及太仓设施通过了OECD的GLP现场检查及复查。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}